Net margin is calculated as Net Income divided by its Revenue. Cuorips's Net Income for the
six
months ended in Mar. 2026 was 円-539.1 Mil. Cuorips's Revenue for the
six
months ended in Mar. 2026 was 円19.6 Mil. Therefore, Cuorips's net margin for the quarter that ended in Mar. 2026 was -2,746.68%.
The historical rank and industry rank for Cuorips's Net Margin % or its related term are showing as below:
TSE:4894'
s Net Margin % Range Over the Past 10 Years
Min: -139924.55 Med: -1939.39 Max: -367.76
Current: -481.62
TSE:4894's Net Margin % is ranked worse than 70.82% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs TSE:4894: -481.62
Cuorips (TSE:4894) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cuorips Net Margin % Related Terms
Cuorips Net Margin % Historical Data
* Premium members only.
The historical data trend for Cuorips's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4894 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Cuorips's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cuorips Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cuorips's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cuorips's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cuorips (TSE:4894) has a Net Margin % of -2,746.68% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Cuorips and its competitors. According to the industry distribution chart, Cuorips ranks #670 out of 946 companies in the Biotechnology industry, placing it in the top 70.8%.
Is Cuorips' Net Margin % too high?
Cuorips' current Net Margin % is -2,746.68%. Based on the distribution chart, Cuorips ranks #670 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cuorips has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cuorips' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cuorips ranks #670 out of 946 companies for Net Margin %. This places Cuorips in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cuorips and its competitors. Cuorips's current Net Margin % is -2,746.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cuorips stock overvalued right now?
Based on GuruFocus' analysis, Cuorips (TSE:4894) is currently considered Possible Value Trap. The stock's GF Value™ is 円28,569.75, compared to a current price of 円3,855.00 — trading 86.5% below its estimated fair value. The current Net Margin % is -2,746.68%. Cuorips' overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cuorips (TSE:4894), the current Net Margin % is -2,746.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cuorips (TSE:4894) Overvalued in 2026?
Based on GuruFocus' analysis, Cuorips stock appears to be undervalued.
The current stock price of 円3,855.00 is trading 86.5% below its estimated GF Value™ of 円28,569.75.
GuruFocus considers Cuorips to be Possible Value Trap.
Key valuation signals for TSE:4894:
Net Margin %: -2,746.68%
GF Value™: 円28,569.75 vs. price of 円3,855.00 (86.5% below fair value)
No single metric tells the full story. See the TSE:4894 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cuorips Inc is engaged in the Research, development, manufacturing, and sales of Cellular and Tissue-based Products and Cell processing products. The company is also engaged in Contract development and manufacturing services and consulting services of Cellular and Tissue-based Products and Cell processing product.
69GF Score
Get the complete analysis for TSE:4894
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4894 has been successfully added to your 
